Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

ProQR Therapeutics stock

PRQR
NL0010872495
A12B97

Price

2.68
Today +/-
+0.33
Today %
+13.12 %

ProQR Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ProQR Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ProQR Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ProQR Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ProQR Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ProQR Therapeutics Stock Price History

DateProQR Therapeutics Price
12/17/20242.68 undefined
12/16/20242.35 undefined
12/13/20242.69 undefined
12/12/20243.14 undefined
12/11/20243.22 undefined
12/10/20243.14 undefined
12/9/20243.27 undefined
12/6/20243.37 undefined
12/5/20243.34 undefined
12/4/20243.30 undefined
12/3/20243.49 undefined
12/2/20243.55 undefined
11/29/20243.63 undefined
11/27/20243.47 undefined
11/26/20243.28 undefined
11/25/20243.37 undefined
11/22/20243.47 undefined
11/21/20243.45 undefined
11/20/20243.48 undefined
11/19/20243.40 undefined
11/18/20243.44 undefined

ProQR Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ProQR Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ProQR Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ProQR Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ProQR Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ProQR Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ProQR Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ProQR Therapeutics’s growth potential.

ProQR Therapeutics Revenue, EBIT and net profit per share

DateProQR Therapeutics RevenueProQR Therapeutics EBITProQR Therapeutics Net Income
2029e94.72 M undefined-22.82 M undefined0 undefined
2028e97.32 M undefined-2.96 M undefined0 undefined
2027e14.69 M undefined-71.41 M undefined0 undefined
2026e17.34 M undefined-54.09 M undefined-49.76 M undefined
2025e26.8 M undefined-38.22 M undefined-39.61 M undefined
2024e31.01 M undefined-41.23 M undefined-30.97 M undefined
20239.53 M undefined-31.86 M undefined-28.12 M undefined
20224.8 M undefined-64.72 M undefined-65.11 M undefined
20212.4 M undefined-57.19 M undefined-61.62 M undefined
20209.45 M undefined-42.37 M undefined-46.57 M undefined
20191.93 M undefined-57.45 M undefined-56.48 M undefined
20185.76 M undefined-36.29 M undefined-36.89 M undefined
20171.5 M undefined-40.5 M undefined-43.64 M undefined
20161.83 M undefined-39.57 M undefined-39.1 M undefined
20153.24 M undefined-27 M undefined-20.83 M undefined
2014310,000 undefined-16.46 M undefined-12.13 M undefined
2013120,000 undefined-3.24 M undefined-3.25 M undefined
201220,000 undefined-420,000 undefined-420,000 undefined

ProQR Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000311519249312617149794
-----66.67-400.00-80.00800.00-77.78100.00125.00244.44-16.13-34.62-17.65592.86-3.09
------------------
000000000000000000
0-3-12-20-39-43-36-56-46-61-65-28-30-39-49000
--300.0066.6795.0010.26-16.2855.56-17.8632.616.56-56.927.1430.0025.64---
20.9620.9623.3423.3423.3525.3734.0541.0450.0664.1871.6481.01000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The ProQR Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ProQR Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
0.24.1112.794.959.248.1105.611275.8187.594.8118.93
000000000000
000000000000
000000000000
00.10.82.41.72.41.82.43.83.731.32
0.24.2113.597.360.950.5107.4114.479.6191.297.8120.24
00.21.22.23.42.51.92.418.617.516.216.9
00000004001006006000
000000000000
002001001000000000
000000000000
000000000000
00.21.42.33.52.51.92.818.718.116.816.9
0.24.4114.999.664.453109.3117.298.3209.3114.6137.14
                       
000000000000
00123.6123.6123.6148.8237.5289.4290.9401.3415.9416.26
00-15.8-36.6-75.7-119.4-155.4-211.7-257.7-317.8-380.7-400.85
0.1-0.11.62.85.31010.916.723.930.330.325.98
000000000000
0.1-0.1109.489.853.239.49394.457.1113.865.541.39
0.10.71.20.90.30.50.10.40.20.20.41.54
000.30.20.3100.101.21.11.66
00.31.44.46.1589.67.719.915.729.39
000000000000
02.5000200.92.46.33.91.61
0.13.52.95.56.78.58.11110.327.621.134.2
0.112.84.85.75.39.412.731.954.118.118.12
000000000000
00000000014.76744.17
0.112.84.85.75.39.412.731.968.885.162.29
0.24.55.710.312.413.817.523.742.296.4106.296.49
0.34.4115.1100.165.653.2110.5118.199.3210.2171.7137.88
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ProQR Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ProQR Therapeutics's financial health and stability.

Assets

ProQR Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ProQR Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ProQR Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ProQR Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
0-3-12-20-39-43-37-56-46-61-64-27
000011022222
000000000000
00111012-622-950
00-3-34111117111650
000000001230
000000000000
0-2-14-24-34-34-28-43-47-26-6821
00-1-1-2000000-1
00-1-1-20000004
000000000005
000000000000
031100111326-45-2
03118002585480110140
061191026865014136-30-2
------------
000000000000
03108-17-35-11576-36111-9224
-0.37-2.47-15.69-25.55-36.76-35.07-28.8-44.55-47.98-26.49-69.2220.18
000000000000

ProQR Therapeutics stock margins

The ProQR Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ProQR Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ProQR Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ProQR Therapeutics's sales revenue. A higher gross margin percentage indicates that the ProQR Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ProQR Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ProQR Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ProQR Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ProQR Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ProQR Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ProQR Therapeutics Margin History

ProQR Therapeutics Gross marginProQR Therapeutics Profit marginProQR Therapeutics EBIT marginProQR Therapeutics Profit margin
2029e0 %-24.09 %0 %
2028e0 %-3.04 %0 %
2027e0 %-486.11 %0 %
2026e0 %-312 %-287.01 %
2025e0 %-142.65 %-147.82 %
2024e0 %-132.96 %-99.87 %
20230 %-334.48 %-295.21 %
20220 %-1,348.33 %-1,356.46 %
20210 %-2,382.92 %-2,567.5 %
20200 %-448.36 %-492.8 %
20190 %-2,976.68 %-2,926.43 %
20180 %-630.03 %-640.45 %
20170 %-2,700 %-2,909.33 %
20160 %-2,162.3 %-2,136.61 %
20150 %-833.33 %-642.9 %
20140 %-5,309.68 %-3,912.9 %
20130 %-2,700 %-2,708.33 %
20120 %-2,100 %-2,100 %

ProQR Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The ProQR Therapeutics earnings per share therefore indicates how much revenue ProQR Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ProQR Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ProQR Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ProQR Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ProQR Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ProQR Therapeutics Revenue, EBIT and net profit per share

DateProQR Therapeutics Sales per ShareProQR Therapeutics EBIT per shareProQR Therapeutics Earnings per Share
2029e0.89 undefined0 undefined0 undefined
2028e0.92 undefined0 undefined0 undefined
2027e0.14 undefined0 undefined0 undefined
2026e0.16 undefined0 undefined-0.47 undefined
2025e0.25 undefined0 undefined-0.37 undefined
2024e0.29 undefined0 undefined-0.29 undefined
20230.12 undefined-0.39 undefined-0.35 undefined
20220.07 undefined-0.9 undefined-0.91 undefined
20210.04 undefined-0.89 undefined-0.96 undefined
20200.19 undefined-0.85 undefined-0.93 undefined
20190.05 undefined-1.4 undefined-1.38 undefined
20180.17 undefined-1.07 undefined-1.08 undefined
20170.06 undefined-1.6 undefined-1.72 undefined
20160.08 undefined-1.69 undefined-1.67 undefined
20150.14 undefined-1.16 undefined-0.89 undefined
20140.01 undefined-0.71 undefined-0.52 undefined
20130.01 undefined-0.15 undefined-0.16 undefined
20120 undefined-0.02 undefined-0.02 undefined

ProQR Therapeutics business model

ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight. ProQR Therapeutics is one of the most popular companies on Eulerpool.com.

ProQR Therapeutics SWOT Analysis

Strengths

ProQR Therapeutics NV has several strengths that contribute to its success in the biopharmaceutical industry. These strengths include:

  • Cutting-edge technology platform allowing efficient development of RNA-based therapeutics.
  • Strong intellectual property portfolio protecting its innovative products.
  • Experienced and skilled management team with a track record of successful drug development.
  • Collaborations with leading academic institutions and pharmaceutical companies, enabling access to knowledge and resources.

Weaknesses

Despite its strengths, ProQR Therapeutics NV also faces certain weaknesses that can pose challenges to its growth and competitiveness:

  • Reliance on a relatively small pipeline with limited product diversity.
  • Dependency on external funding sources for research and development activities.
  • Highly regulated industry, resulting in lengthy and costly drug development processes.
  • Limited market access and potential competition from larger, well-established pharmaceutical companies.

Opportunities

ProQR Therapeutics NV can leverage various opportunities in the market to enhance its growth and market position:

  • Increasing demand for targeted and personalized therapies, aligning with the company's RNA-based platform.
  • Expanding partnerships and collaborations to access new technologies, expertise, and potential funding.
  • Advancements in RNA-based therapeutics and gene therapies, opening up new treatment possibilities.
  • Growing prevalence of genetic diseases and disorders, creating a larger patient population for ProQR's products.

Threats

ProQR Therapeutics NV faces certain threats that could impact its business operations and market performance:

  • Intense competition from other biopharmaceutical companies developing similar RNA-based therapies.
  • Stringent regulatory requirements and potential delays in obtaining approvals for new drugs.
  • Uncertainties in intellectual property protection, potential patent disputes, and generic competition.
  • Volatility and unpredictability of financial markets, affecting the ability to secure funding for research and development.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ProQR Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ProQR Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ProQR Therapeutics shares outstanding

The number of shares was ProQR Therapeutics in 2023 — This indicates how many shares 81.011 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ProQR Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ProQR Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ProQR Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ProQR Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for ProQR Therapeutics.

ProQR Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.11 -0.1  (7.06 %)2024 Q3
6/30/2024-0.13 -0.03  (76.42 %)2024 Q2
3/31/2024-0.11 -0.09  (19.43 %)2024 Q1
12/31/20230.01 -0.07  (-730.63 %)2023 Q4
9/30/2023-0.09 -0.07  (19.35 %)2023 Q3
6/30/2023-0.11 -0.1  (11.74 %)2023 Q2
3/31/2023-0.12 -0.11  (8.33 %)2023 Q1
12/31/2022-0.18 -0.16  (12.14 %)2022 Q4
9/30/2022-0.21 -0.34  (-58.29 %)2022 Q3
6/30/2022-0.22 -0.21  (4.63 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the ProQR Therapeutics stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

72

👫 Social

86

🏛️ Governance

47

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ProQR Therapeutics shareholders

%
Name
Stocks
Change
Date
12.62659 % Eli Lilly and Company13,371,562012/31/2023
7.71507 % Van Herk Investments8,170,2541,024,0352/9/2024
5.26981 % Privium Fund Management BV5,580,725236,2796/30/2024
3.42348 % Adage Capital Management, L.P.3,625,46706/30/2024
1.92896 % EcoR1 Capital, LLC2,042,771-841,5866/30/2024
0.96270 % M28 Capital Management LP1,019,49806/30/2024
0.85513 % Dafna Capital Management, LLC905,58206/30/2024
0.84986 % Ghost Tree Capital, LLC900,000900,0006/30/2024
0.75543 % De Grote Voskuil Capital B.V.800,00006/30/2024
0.68526 % Valerio (Dinko)725,692-134,63612/31/2023
1
2
3
4
5
...
10

ProQR Therapeutics Executives and Management Board

Mr. Daniel De Boer

(40)
ProQR Therapeutics Chairman of the Management Board, Chief Executive Officer
Compensation 2.46 M

Mr. Rene Beukema

(59)
ProQR Therapeutics Chief Corporate Development Officer, General Counsel (since 2022)
Compensation 463,000

Mr. Dinko Valerio

(66)
ProQR Therapeutics Chairman of the Supervisory Board (since 2014)
Compensation 178,000

Dr. James Shannon

(66)
ProQR Therapeutics Independent Member of the Supervisory Board
Compensation 163,000

Ms. Alison Lawton

(61)
ProQR Therapeutics Independent Member of the Supervisory Board
Compensation 156,000
1
2
3

Most common questions regarding ProQR Therapeutics

What values and corporate philosophy does ProQR Therapeutics represent?

ProQR Therapeutics NV is committed to transforming the lives of patients with severe genetic diseases. Their corporate philosophy revolves around innovation, collaboration, and dedication to scientific excellence. With a focus on RNA therapies, ProQR Therapeutics NV aims to develop life-changing treatments using proprietary technologies and expertise. Their values include patient-centricity, integrity, and a strong sense of responsibility towards their stakeholders. By leveraging their extensive knowledge and strategic partnerships, ProQR Therapeutics NV strives to address unmet medical needs and improve the quality of life for individuals affected by genetic disorders.

In which countries and regions is ProQR Therapeutics primarily present?

ProQR Therapeutics NV is primarily present in multiple countries and regions globally. The company has a strong presence in Europe, with headquarters in the Netherlands. It operates extensively within the European Union, including countries like Germany, France, and the United Kingdom. ProQR has also expanded its reach into North America, specifically the United States. Additionally, the company has established a presence in various international markets, such as Japan. ProQR Therapeutics NV's global presence allows it to access diverse markets and collaborate with partners worldwide to advance its innovative therapies and treatments.

What significant milestones has the company ProQR Therapeutics achieved?

ProQR Therapeutics NV, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 1b clinical trial for its Usher syndrome therapy, QR-421a. It also advanced its RNA therapeutics for cystic fibrosis (QR-010) into Phase 2 trials, showcasing promising results. ProQR Therapeutics NV received Fast Track designation from the U.S. FDA for its Leber Congenital Amaurosis program (QR-110), accelerating its development. Moreover, the company's QR-313 therapeutic, targeting dystrophic epidermolysis bullosa, obtained Orphan Drug designation from the FDA and European Medicines Agency. ProQR Therapeutics NV's commitment to innovative solutions and achieving significant clinical milestones positions it favorably in the pharmaceutical industry.

What is the history and background of the company ProQR Therapeutics?

ProQR Therapeutics NV is a leading biotech company focused on developing innovative RNA-based therapies to treat genetic diseases. Founded in 2012 and headquartered in the Netherlands, ProQR pioneers the development of RNA therapies by leveraging a proprietary technology platform. The company's objective is to address the root cause of diseases at the genetic level, aiming to transform the lives of patients with severe genetic disorders. ProQR's pipeline comprises targeted therapies for a variety of indications, including rare eye diseases, cystic fibrosis, and genetic muscle disorders. With its commitment to advancing groundbreaking treatments, ProQR Therapeutics NV stands at the forefront of biotech innovation.

Who are the main competitors of ProQR Therapeutics in the market?

The main competitors of ProQR Therapeutics NV in the market are Editas Medicine, Ionis Pharmaceuticals, and Vertex Pharmaceuticals.

In which industries is ProQR Therapeutics primarily active?

ProQR Therapeutics NV is primarily active in the biotechnology industry.

What is the business model of ProQR Therapeutics?

The business model of ProQR Therapeutics NV is centered around developing RNA-based therapeutics to treat rare and genetic diseases. By utilizing proprietary RNA repair technologies, the company aims to target specific genetic defects and correct them at the molecular level. ProQR Therapeutics NV conducts extensive research and clinical trials to develop innovative treatments for various conditions, including cystic fibrosis, Leber's congenital amaurosis, and rare forms of genetic blindness. Through strategic partnerships, they aim to advance their pipeline of candidate therapies and ultimately improve the lives of patients affected by these diseases.

What is the P/E ratio of ProQR Therapeutics 2024?

The ProQR Therapeutics P/E ratio is -7.01.

What is the P/S ratio of ProQR Therapeutics 2024?

The ProQR Therapeutics P/S ratio is 7.

What is the Quality Investing of ProQR Therapeutics?

The Quality Investing for ProQR Therapeutics is 5/10.

What is the revenue of ProQR Therapeutics 2024?

The expected ProQR Therapeutics revenue is 31.01 M EUR.

How high is the profit of ProQR Therapeutics 2024?

The expected ProQR Therapeutics profit is -30.97 M EUR.

What is the business model of ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceutical company that focuses on RNA-based therapeutics for the treatment of genetically inherited diseases. With over a decade of company history, it has become one of the leading companies in the field of RNA medicine. The business model of ProQR Therapeutics NV is based on the discovery, development, and commercialization of RNA technologies and products. With a strong focus on identifying genetic mutations that lead to diseases, the company focuses on developing RNA-based therapies to treat these diseases. One area that the company focuses on is ophthalmological research. ProQR Therapeutics NV has established itself as a pioneer in RNA medicine for the treatment of eye diseases. The company has developed an RNA technology platform called "Axiomer" specifically to enable the treatment of retinal diseases. Another area that ProQR Therapeutics NV focuses on is pulmonary research. The company hopes to provide life-changing treatments for patients with cystic fibrosis and other pulmonary diseases through RNA therapies. The company also has a strong presence in nephrology. An RNA therapeutic has been developed to treat IQ motif-containing GTPase-activating protein 2 (IQGAP2), which is a key factor in the development of a rare and severe progressive kidney disease called ADPKD (autosomal dominant polycystic kidney disease). In addition, the company works closely with leading research and development institutions to further develop and improve RNA technologies. ProQR Therapeutics NV has partnerships with various renowned institutions, including the National Institutes of Health (NIH), the Cystic Fibrosis Foundation, and the Usher Syndrome Coalition Program. The company has already developed several RNA therapeutics and is bringing these products to market. One such product is QR-010, for which ProQR Therapeutics NV has received an Orphan Drug Designation. The medication is intended for patients with cystic fibrosis and is currently in clinical phase 2b/3. Another product, QR-313, is also in clinical phase for patients with epidermolytic ichthyosis. In addition to these RNA therapeutics, the company also has a robust pipeline for further RNA-based therapies in various stages of development. The company plans to bring these products to market in the coming years. Overall, ProQR Therapeutics NV has a solid business model based on innovative RNA technologies and the development of life-changing therapies for patients with rare and severe diseases. With a strong presence in ophthalmology, nephrology, and pulmonology, and a wide range of RNA products in development, the company seems well-positioned to continue its growth in the coming years.

What is the ProQR Therapeutics dividend?

ProQR Therapeutics pays a dividend of 0 EUR distributed over payouts per year.

How often does ProQR Therapeutics pay dividends?

The dividend cannot currently be calculated for ProQR Therapeutics or the company does not pay out a dividend.

What is the ProQR Therapeutics ISIN?

The ISIN of ProQR Therapeutics is NL0010872495.

What is the ProQR Therapeutics WKN?

The WKN of ProQR Therapeutics is A12B97.

What is the ProQR Therapeutics ticker?

The ticker of ProQR Therapeutics is PRQR.

How much dividend does ProQR Therapeutics pay?

Over the past 12 months, ProQR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ProQR Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of ProQR Therapeutics?

The current dividend yield of ProQR Therapeutics is .

When does ProQR Therapeutics pay dividends?

ProQR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ProQR Therapeutics?

ProQR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ProQR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is ProQR Therapeutics located?

ProQR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ProQR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ProQR Therapeutics from 12/17/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did ProQR Therapeutics pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of ProQR Therapeutics in the year 2023?

In the year 2023, ProQR Therapeutics distributed 0 EUR as dividends.

In which currency does ProQR Therapeutics pay out the dividend?

The dividends of ProQR Therapeutics are distributed in EUR.

All fundamentals about ProQR Therapeutics

Our stock analysis for ProQR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ProQR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.